ABL Bio, Inc.
๐ฐ๐ทSouth Korea
- Country
- ๐ฐ๐ทSouth Korea
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 102
- Market Cap
- -
- Website
- http://www.ablbio.com
A Study with ABL103 in Subjects with Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- ABL Bio, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT06126666
- Locations
- ๐ฐ๐ท
Seoul National University Bundang Hospital, Seongnam, Seoul, Korea, Republic of
๐ฐ๐ทSevrance Hospital, Seoul, South Korea, Korea, Republic of
๐ฐ๐ทSeoul National University Hospital, Seoul, Korea, Republic of
This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- ABL Bio, Inc.
- Target Recruit Count
- 86
- Registration Number
- NCT05756920
- Locations
- ๐บ๐ธ
PPD Development, LP, Austin, Texas, United States
Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- ABL Bio, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05101109
- Locations
- ๐ฐ๐ท
Samsung Medical Center, Seoul, Korea, Republic of
๐ฐ๐ทSeoul National University Bundang Hospital, Seoul, Korea, Republic of
๐ฐ๐ทAsan Medical Center, Seoul, Korea, Republic of
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- ABL Bio, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04762641
- Locations
- ๐บ๐ธ
City of Hope, Duarte, California, United States
๐บ๐ธUSC, LA, California, United States
๐บ๐ธUCLA, Santa Monica, California, United States
This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: NOV1501 (ABL001)
- First Posted Date
- 2017-09-26
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- ABL Bio, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT03292783
- Locations
- ๐ฐ๐ท
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
๐ฐ๐ทSamsung Medical Center, Seoul, Korea, Republic of
ยฉ Copyright 2025. All Rights Reserved by MedPath